DDInter1232 DDInter596
Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discovered that work via this alkylating mechanism, making mitomycin relatively unique in the space of microbiota-derived therapies. Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper Tract Urothelial Cancer (LG-UTUC) - as well as adjunctly to _ab externo_ glaucoma surgeries.
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers.[A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with poor heart function and requires treatment termination once the maximally tolerated cumulative dose is reached.
Mitomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Mitomycin {u} (Compound) treats {v} (Disease) stomach cancer
stomach cancer {u} (Disease) is treated by {v} (Compound) Doxorubicin
Mitomycin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Mitomycin {u} (Compound) upregulates {v} (Gene) E2F2
E2F2 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Mitomycin {u} (Compound) downregulates {v} (Gene) TSKU
TSKU {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Mitomycin {u} (Compound) upregulates {v} (Gene) TBP
TBP {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Mitomycin {u} (Compound) causes {v} (Side Effect) Feeling abnormal
Feeling abnormal {u} (Side Effect) is caused by {v} (Compound) Doxorubicin
Mitomycin {u} (Compound) downregulates {v} (Gene) TOP2A
TOP2A {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Mitomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Valrubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Mitomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Mitomycin (Compound) treats stomach cancer (Disease) and stomach cancer (Disease) is treated by Doxorubicin (Compound)
Mitomycin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxorubicin (Compound)
Mitomycin (Compound) upregulates E2F2 (Gene) and E2F2 (Gene) is upregulated by Doxorubicin (Compound)
Mitomycin (Compound) downregulates TSKU (Gene) and TSKU (Gene) is downregulated by Doxorubicin (Compound)
Mitomycin (Compound) upregulates TBP (Gene) and TBP (Gene) is downregulated by Doxorubicin (Compound)
Mitomycin (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Doxorubicin (Compound)
Mitomycin (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is bound by Doxorubicin (Compound) and TOP2A (Gene) is downregulated by Doxorubicin (Compound)
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Valrubicin (Compound) and Valrubicin (Compound) resembles Doxorubicin (Compound)
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin (Compound) resembles Daunorubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)